Price$3.37-0.87 (-20.43%)
2026-03-052026-06-08
News · 26 weeks330%
2025-12-142026-06-07
Mix1390d
- SEC Filings8(62%)
- Other5(38%)
Latest news
25 items- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form 10-Q filed by Lisata Therapeutics Inc.10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Lisata Therapeutics Inc.10-K/A - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECSEC Form 8-K filed by Lisata Therapeutics Inc.8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECSEC Form 10-K filed by Lisata Therapeutics Inc.10-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRLisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously approved the transaction and recommends that stockholders tender their shares Transaction expected to close in the second quarter of 2026 BASKING RIDGE, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has entered into a definitive agreement to be acquired by Kuva La
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRLisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for CertepetideBASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical Co., Ltd. ("Qilu"). The original agreement, negotiated and implemented with CEND Therapeutics and assumed by Lisata as part of its acquisition of CEND Therapeutics in 2022, granted Qilu exclusive rights to develop and commercialize certepetide, Lisata's proprietary iRGD cyclic peptide product
- SECSEC Form SC14D9C filed by Lisata Therapeutics Inc.SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRLisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender OfferStockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent closing price of Lisata stock BASKING RIDGE, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has entered into a binding term sheet to be acquired by Kuva Labs, Inc. ("Kuva"), a privately-held company. Pursuant to the terms and conditions of the term
- INSIDERPresident & CEO Mazzo David J was granted 81,000 shares and covered exercise/tax liability with 41,096 shares, increasing direct ownership by 15% to 311,890 units (SEC Form 4)4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSVP, Fin/Treas, Chief Actg Off Nisco James was granted 15,000 shares and covered exercise/tax liability with 6,180 shares, increasing direct ownership by 38% to 32,311 units (SEC Form 4)4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
LSTA FAQ
4 questionsWhere does LSTA stock trade?
Lisata Therapeutics Inc. (LSTA) is listed on NASDAQ.What sector and industry is LSTA in?
Lisata Therapeutics Inc. operates in the Health Care sector, Misc Health and Biotechnology Services industry.What companies are similar to LSTA?
Notable peers in the same industry include DVA (DaVita Inc.), FMS (Fresenius Medical Care AG), SHC (Sotera Health Company), PGNY (Progyny Inc.), AGL (agilon health inc.). Compare LSTA side-by-side with any of them on Quantisnow.How can I track LSTA on Quantisnow?
Quantisnow aggregates Lisata Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LSTA to receive live email and push alerts on every new disclosure.